People seeking psychiatric healing choose from an almost dizzying array of therapies--from the medicated mud packs of Ayurveda, to the pharmacopeia of Western biomedicine, to the spiritual pathways of the world's religions. How do we choose, what do the treatments offer, and how do they cure? In Mudpacks and Prozac, Murphy Halliburton investigates the very different ways in which Ayurvedic, Western, and religious (Christian, Muslim, and Hindu) healing systems define psychiatric problems and cures. He describes people's embodied experiences of therapies that range from soothing to frightening, and explores how enduring pleasure or pain affects healing. And through evocative portraits of patients in Kerala, India--a place of incredible cultural diversity that has become a Mecca for alternative medicine--Halliburton shows how sociopolitical changes around the globe may be limiting the ways in which people seek and experience health care, with negative effects on our quality of health and quality of life.

People seeking psychiatric healing choose from an almost dizzying array of therapies--from the medicated mud packs of Ayurveda, to the pharmacopeia of Western biomedicine, to the spiritual pathways of the world's religions. How do we choose, what do the treatments offer, and how do they cure? In Mudpacks and Prozac, Murphy Halliburton investigates the very different ways in which Ayurvedic, Western, and religious (Christian, Muslim, and Hindu) healing systems define psychiatric problems and cures. He describes people's embodied experiences of therapies that range from soothing to frightening, and explores how enduring pleasure or pain affects healing. And through evocative portraits of patients in Kerala, India--a place of incredible cultural diversity that has become a Mecca for alternative medicine--Halliburton shows how sociopolitical changes around the globe may be limiting the ways in which people seek and experience health care, with negative effects on our quality of health and quality of life.

India and the Patent Wars contributes to an international debate over the costs of medicine and restrictions on access under stringent patent laws showing how activists and drug companies in low-income countries seize agency and exert influence over these processes. Murphy Halliburton contributes to analyses of globalization within the fields of anthropology, sociology, law, and public health by drawing on interviews and ethnographic work with pharmaceutical producers in India and the United States. India has been at the center of emerging controversies around patent rights related to pharmaceutical production and local medical knowledge. Halliburton shows that Big Pharma is not all-powerful, and that local activists and practitioners of ayurveda, India's largest indigenous medical system, have been able to undermine the aspirations of multinational companies and the WTO. Halliburton traces how key drug prices have gone down, not up, in low-income countries under the new patent regime through partnerships between US- and India-based companies, but warns us to be aware of access to essential medicines in low- and middle-income countries going forward.

India and the Patent Wars contributes to an international debate over the costs of medicine and restrictions on access under stringent patent laws showing how activists and drug companies in low-income countries seize agency and exert influence over these processes. Murphy Halliburton contributes to analyses of globalization within the fields of anthropology, sociology, law, and public health by drawing on interviews and ethnographic work with pharmaceutical producers in India and the United States. India has been at the center of emerging controversies around patent rights related to pharmaceutical production and local medical knowledge. Halliburton shows that Big Pharma is not all-powerful, and that local activists and practitioners of ayurveda, India's largest indigenous medical system, have been able to undermine the aspirations of multinational companies and the WTO. Halliburton traces how key drug prices have gone down, not up, in low-income countries under the new patent regime through partnerships between US- and India-based companies, but warns us to be aware of access to essential medicines in low- and middle-income countries going forward.